Company Overview of GlycoMimetics, Inc.
GlycoMimetics, Inc., a clinical stage biotechnology company, focuses on the discovery and development of glycomimetic drugs to address unmet medical needs resulting from diseases in the United States. The company develops lead product rivipansel, a glycomimetic drug candidate that has completed Phase II clinical trials for the treatment of vaso-occlusive crisis, a debilitating and painful condition that occurs periodically throughout the life of a person with sickle cell disease. It also develops GMI-1271, a specific E-selectin antagonist to treat acute myeloid leukemia and other hematologic cancers; and GMI-1051 and other drug candidates for pseudomonas virulence factors. The company has a ...
401 Professional Drive
Gaithersburg, MD 20879
Founded in 2003
Key Executives for GlycoMimetics, Inc.
Co-Founder, Chief Executive Officer, President and Director
Total Annual Compensation: $417.0K
Chief Financial Officer and Principal Accounting Officer
Total Annual Compensation: $285.4K
Chief Medical Officer and Vice President of Clinical Development
Total Annual Compensation: $345.0K
Chief Scientific Officer, Vice President of Research and Director
Total Annual Compensation: $309.8K
Compensation as of Fiscal Year 2014.
GlycoMimetics, Inc. Key Developments
GlycoMimetics Announces Initiation of Phase 3 Clinical Trial Assessing the Efficacy and Safety of Rivipansel for the Treatment of Vaso-Occlusive
Jun 24 15
GlycoMimetics announced the initiation of a Phase 3 clinical trial assessing the efficacy and safety of rivipansel for the treatment of vaso-occlusive crisis in patients hospitalized with sickle cell disease in partnership with Pfizer Inc. The dosing of the first patient under this Phase 3 clinical trial has triggered the second of two milestone payments from Pfizer to GlycoMimetics totaling USD 35 million. Under the partnership, Pfizer dosed the first patient in the RESET (Rivipansel: Evaluating Safety, Efficacy and Time to Discharge) study, which is a Phase 3 clinical trial assessing the efficacy and safety of rivipansel for treating vaso-occlusive crisis in patients hospitalized with sickle cell disease who are six years of age or older. In conjunction with the trial, the primary endpoint for the study will be time to readiness-for-discharge. Key secondary endpoints will include time to discharge, cumulative IV opioid consumption and time to discontinuation of IV opioids. Sickle cell disease is a genetic disease affecting people in the US, predominantly of African descent. One of the most severe complications of sickle cell disease is vaso-occlusive crisis, which is typically characterized by excruciating, debilitating pain that occurs periodically throughout the life of a person with sickle cell disease.
GlycoMimetics, Inc. Presents at BIO International Convention 2015, Jun-17-2015 10:00 AM
Jun 11 15
GlycoMimetics, Inc. Presents at BIO International Convention 2015, Jun-17-2015 10:00 AM. Venue: Pennsylvania Convention Center, Philadelphia, Pennsylvania, United States. Speakers: Armand Girard, Vice President of Corporate Development.
GlycoMimetics, Inc. Initiates Phase 1/2 Clinical Trial of GMI-1271 as Potential Treatment for Acute Myeloid Leukemia in Combination with Chemotherapy
May 19 15
GlycoMimetics, Inc. announced that the first patient has been dosed in a Phase 1/2 clinical study designed to evaluate the safety, pharmacokinetics (PK) and efficacy of GMI-1271, a novel and proprietary E-selectin antagonist in the company’s pipeline, when used in combination with chemotherapy in patients with acute myeloid leukemia (AML). GlycoMimetics is initially exploring the clinical use of the drug candidate in hematologic malignancies following the successful completion of a Phase 1 healthy volunteer study late last year. The Company announced last week that the U.S. Food & Drug Administration (FDA) has granted Orphan Drug designation to GMI-1271 for treatment of AML. This Phase 1/2, open-label multicenter study is designed to determine safety, PK and efficacy of GMI-1271 in combination with chemotherapy in male and female adult patients with AML. Study sites are located in the United States, Australia and Ireland. While the primary objective is to analyze safety, additional endpoints include: mobilization of AML blasts, effect on neutropenia, time to and duration of remission, evaluation of event-free survival and evaluation of the overall survival probability at six- and 12-months. Approximately 77 subjects will be enrolled. The study will include a dose escalation phase followed by expansion of the study once the dose for the Phase 2 portion has been selected. AML: Adult acute myeloid leukemia (AML) is a cancer of the blood and bone marrow. AML is the most common type of acute leukemia in adults, and it is estimated that there will be over 18,000 new cases and over 10,000 deaths from the disease in 2014. Unlike other cancers that start in an organ and spread to the bone marrow, AML is known for rapid growth of abnormal white blood cells that gather in the bone marrow and as a result, impede normal blood cell production. While leukemic cells move into the blood, the lack of normal blood cells can cause some of the symptoms of AML, including anemia (shortage of red blood cells resulting in tiredness and weakness), neutropenia (shortage of white blood cells that may lead to increased infections), and thrombocytopenia (shortage of platelets in the blood that may lead to excessive bleeding). Current treatment options for AML are chemotherapy and stem cell transplantation, both of which can destroy cancer cells but do not reduce the related side effects.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|